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The beneﬁts of statins, commonly prescribed for hypercholesterolemia, in treating
Alzheimer’s disease (AD) have not yet been fully established. A recent randomized
clinical trial did not show any therapeutic effects of two statins on cognitive function
in AD. Interestingly, however, the results of the Rotterdam study, one of the largest
prospective cohort studies, showed reduced risk of AD in statin users. Based on the
current understanding of statin actions and AD pathogenesis, it is still worth exploring
whether statins can prevent AD when administered decades before the onset of AD or
from midlife. This review discusses the possible beneﬁcial effects of statins, drawn from
previous clinical observations, pathogenic mechanisms, which include β-amyloid (Aβ) and
tau metabolism, genetic and non-genetic risk factors (apolipoprotein E, cholesterol, sex,
hypertension, and diabetes), and other clinical features (vascular dysfunction and oxidative
and inﬂammatory stress) of AD. These ﬁndings suggest that administration of statins in
midlife might prevent AD in late life by modifying genetic and non-genetic risk factors
for AD. It should be clariﬁed whether statins inhibit Aβ accumulation, tau pathological
features, and brain atrophy in humans. To answer this question, a randomized controlled
study using amyloid positron emission tomography (PET), tau-PET, andmagnetic resonance
imaging would be useful.This clinical evaluation could help us to overcome this devastating
disease.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia.
The dramatic increase of life expectancy has resulted in an increas-
ing number of patients with AD, imposing social and economic
burden (Alzheimer’s Association, 2013). The neuropathological
hallmarks of the disease include accumulation of senile plaques,
composed of β-amyloid (Aβ), and neuroﬁbrillary tangles (NFTs),
composed of hyper-phosphorylated tau protein. There is evidence
supporting that Aβ initiates the pathogenesis of AD (Masters and
Beyreuther, 2006; Ballard et al., 2011). However, the failure of
clinical trials of “anti-Aβ” therapies indicates that the interven-
tion should be applied earlier, because Aβ deposition commences
decades before the development of clinical symptoms of AD
(Burns, 2009; Jack et al., 2010).
Interestingly, a prospective cohort study suggested that use
of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors, or statins, which are widely prescribed for the treat-
ment of hypercholesterolemic patients (Endo, 2008), decreases
the incidence of AD by half. However, controversy exists regarding
whether statins have therapeutic effects on AD. In this review, the
potential effects of statins against AD are addressed by drawing
upon previous basic and clinical studies. Statin use from midlife
could prevent AD.
DYSLIPIDEMIA, AD, AND STATINS
The ﬁrst statin, named “compactin,” was discovered and isolated
from microorganisms by a research team led by Dr. Akira Endo at
Sankyo Co. in 1972 (Endo, 2008). His discovery initially suffered
from the limitations of animal studies, because rodents were resis-
tant to cholesterol reduction by statins (Endo, 2004). Dozens of
studies using larger animals, like chicken, dog, and monkey, and a
clinical study in familial hyperlipidemia patients showed that this
statin reduces plasma low-density lipoprotein (LDL)-cholesterol
level (Mabuchi et al., 1981). Today, several statins are now in
clinical use. Statins reduce cholesterol level via the inhibition of
HMG-CoA reductase in hepatic cells. Sterol regulatory element-
binding proteins (SREBPs) sense this change in cholesterol level,
with a subsequent increase in their LDL receptor (LDLR) expres-
sion to uptake serum LDL cholesterol in order to compensate for
the reduced cellular cholesterol content (Goldstein and Brown,
2009). Then, clinical studies have shown that statins prevent
cardiovascular and cerebrovascular events (Shepherd et al., 1995;
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Crouse et al., 1997; White et al., 2000; Heart Protection Study
Collaborative Group, 2002) by reducing plasma cholesterol level
(Amarenco and Labreuche, 2009; De Caterina et al., 2010) and
regulating an isoprenoid pathway (Downs et al., 1998; Sever et al.,
2003; Zhou and Liao, 2010). Of note, the preventative effects
could be more evident in middle age (Shepherd et al., 1995, 2002;
Heart Protection Study Collaborative Group, 2002).
CLINICAL STUDIES OF STATINS AND AD
It is conceivable that statins prevent strokes, and thereby reduce
the incidence of vascular dementia. However, further studies are
required to clarify whether statins are effective to prevent AD.
Firstly, two case–control studies supported the preventive effect
of statins on AD (Jick et al., 2000; Wolozin et al., 2000), whereas
the results of subsequent studies including prospective studies are
controversial (Heart Protection Study Collaborative Group, 2002;
Shepherd et al., 2002; Zamrini et al., 2004; Dufouil et al., 2005;
Rea et al., 2005; Zandi et al., 2005; Sparks et al., 2008; Haag et al.,
2009; Feldman et al., 2010; Sano et al., 2011; Bettermann et al.,
2012). Two recent randomized clinical studies enrolling around
400 mild-to-moderate AD patients have failed to show beneﬁts of
atorvastatin and simvastatin on cognitive function (Feldman et al.,
2010; Sano et al., 2011). Although these two randomized studies
could refute the beneﬁcial effects of statins on disease progres-
sion in AD patients, there were several limitations including the
duration of intervention (18-month period) and the selection of
subjects such as the exclusion of AD patients requiring treatment
for dyslipidemia with lipid-lowering agents. On the other hand,
several prospective studies indicate that statins could prevent the
onset of AD (Jick et al., 2000; Sparks et al., 2008; Haag et al., 2009;
Bettermann et al., 2012). Follow-up period and cohort size of such
supportive prospective studies are relatively longer and larger: over
6 years of follow-up and more than 1000 subjects enrolled. A
recent meta-analysis by Wong et al. (2013) also showed preven-
tive effects of statins on AD. Of note, several reports indicated
preventive effects of statins on AD only when they included rela-
tively young subjects (Rockwood et al., 2002; Li et al., 2004, 2010a).
Taken together, these results of previous clinical studies indi-
cate that the preventive effects and therapeutic effects against AD
should be separately considered to elucidate the effects of statins
against AD. Such idea corresponds with current understanding
of “anti-Aβ” therapies: once clinical symptoms develop, other
mechanisms would be required to treat AD (Holmes et al., 2008;
Burns, 2009). Therefore, possible beneﬁts of statins against AD
might be obtained if administered decades before the onset of the
disease.
DIFFERENCES AMONG STATINS
One important aspect to consider in the effects of statins is their
pharmacodynamics and permeability into the brain (Butterﬁeld
et al., 2011). Brain-permeable statins, such as simvastatin and
lovastatin, might readily act on neurons and glia in the brain,
and exert neuroprotective effects including Aβ-lowering effects
(Fassbender et al., 2001; Simons et al., 2002). However, controversy
exists regarding whether brain-permeable statins could be beneﬁ-
cial for AD (Wolozin et al., 2000; Arvanitakis et al., 2008). Among
the studies showing preventive effects of statins on AD, only
sub-analysis in the Ginkgo Evaluation of Memory Study reported
that lipophilic statins tended to reduce the risk of dementia more
than did hydrophilic statins (Bettermann et al., 2012). Notably, in
the Rotterdam study, which showed a risk reduction of AD by
statins, there was no difference in this beneﬁcial effect between
hydrophilic and lipophilic statins (Haag et al., 2009). Although the
results of these studies may suffer limitations of small numbers for
distinguishing hydrophilic and lipophilic statin users, the results of
the latter prospective study suggested that the possible preventive
effects of statins on AD might be due to the common mecha-
nism of action of statins rather than the speciﬁc mechanism of
action of brain-permeable statins. A recent review by Shepardson
et al. (2011) discussed the difﬁculty in attributing the protective
effects of statins to speciﬁc brain-permeable statins, by pointing
out the existence of several confounding effects, including the pre-
scribed dosage, pattern and duration, statistical power, and genetic
risks.
NON-GENETIC RISK FACTORS, AD, AND STATINS
Non-genetic risk factors for AD include age, gender, physical
activity, obesity, midlife hypertension, and diabetes mellitus.
Meta-analyses have shown that the odds ratio of women to develop
AD relative to men is 1.56 (95% CI 1.16–2.10; Jorm and Jolley,
1998). Thus far, no clinical report has recognized the gender-
speciﬁc beneﬁcial effect of statins on AD. A very high dose of
lovastatin of 100 mg/kg/day, equal to around 100 times the human
dose, increasedAβdeposits only in femaleTg2576mice (Park et al.,
2003). Compared to men, women receiving statins may lack risk
reductions in mortality and stroke (Dale et al., 2007). These pre-
clinical and clinical studies imply that statins may also exert a
gender-speciﬁc effect on AD.
OBESITY, AD, AND STATINS
A recent meta-analysis showed that obesity increases the risk of
AD [hazard ratio (HR) 1.80, 95% CI 1.00–3.29; Beydoun et al.,
2008]. Also, it was observed that midlife obesity is associated with
an increased risk of some types of cognitive deﬁcit (Debette et al.,
2011). Statins might have beneﬁts on obesity by increasing the
catabolism of several lipids as well as apolipoprotein B-100, a key
player in central obesity (Watts et al., 2003; Ooi et al., 2008). Regu-
lation of peroxisome proliferator-activated receptor-α through an
isoprenoid pathway also seems to be important for such beneﬁts of
statins (Roglans et al., 2002; Landrier et al., 2004; Paumelle et al.,
2006).
HYPERTENSION, AD, AND STATINS
Several papers report that midlife hypertension is a risk for AD
(Skoog et al., 1996; Launer et al., 2000). This is also supported
by recent clinical studies showing that blood pressure-lowering
therapy can reduce the risk of AD or dementia (Launer et al.,
2010; Li et al., 2010b). A meta-analysis of randomized controlled
trials showed that statins have beneﬁcial effects on hyperten-
sion (Strazzullo et al., 2007). These effects are additive with
those of anti-hypertensive drugs, and occur independently of the
baseline and change in cholesterol levels. This suggests the involve-
ment of pleiotropic effects against hypertension-induced systemic
inﬂammation and oxidative insults through the regulation of
Frontiers in Aging Neuroscience www.frontiersin.org April 2014 | Volume 6 | Article 71 | 2
Shinohara et al. Statins in midlife against Alzheimer’s disease
an isoprenoid pathway, but not blood pressure lowering itself
(Strazzullo et al., 2007). Further analysis of this effect might reveal
a role of statins in the crosstalk between midlife hypertension
and AD.
DIABETES, AD, AND STATINS
A recent meta-analysis of 15 prospective cohort studies revealed
that diabetes also increases the risk of AD (HR 1.39, 95% CI
1.16–1.66; Lu et al., 2009). Interestingly, midlife diabetes seems
to accelerate brain aging such as hippocampal atrophy and cog-
nitive decline (Nooyens et al., 2010; Debette et al., 2011). It is
well known that statin treatment can reduce the risk of coro-
nary artery disease events in patients with diabetes (Kearney
et al., 2008). As the underlying mechanism, regulation of the
receptor for advanced glycation end products, RAGE, an impor-
tant mediator of oxidative and inﬂammatory processes, might
be involved in such statin actions (Lanati et al., 2010; Takeda
et al., 2011). Of note, RAGE could also be an important tar-
get for AD therapy (Deane, 2012). While a meta-analysis of
sub-analysis showed that statins very weakly increase the risk of
diabetes itself (HR 1.09, 95% CI 1.02–1.17; Sattar et al., 2010),
J-PREDICT (Japan Prevention Trial of Diabetes by Pitavastatin in
Patients with Impaired Glucose Tolerance), an only cohort study
whose primary outcome was onset of diabetes, showed a reduc-
tion of incidence of diabetes in statin-treated group (Odawara
et al., 2013). Therefore, these ﬁndings suggest that diabetes may lie
as a confounding factor between statins and AD. Further anal-
ysis is required to access the effect of stain on the incidence
of diabetes, then on that of AD in pre-diabetic and diabetic
patients.
MECHANISMS OF ACTION
EFFECTS OF STATINS ON CHOLESTEROL
Several groups have reported that cholesterol-lowering drugs,
besides statins, decrease Aβ production, while cholesterol itself
increases Aβ production in cell culture and animal studies (Rac-
chi et al., 1997; Simons et al., 1998; Refolo et al., 2000; Kojro et al.,
2001; Shie et al., 2002; Wahrle et al., 2002). Therefore, cholesterol-
lowering could have a possible preventive effect against the onset
of AD, though the role of cholesterol in AD remains unknown
in humans. First, it is controversial whether the systemic choles-
terol level is relevant to the incidence or the progression of AD
(Jarvik et al., 1995; Yoshitake et al., 1995; Notkola et al., 1998;
Romas et al., 1999; Evans et al., 2000; Kivipelto et al., 2002; Tan
et al., 2003; Sabbagh et al., 2004). Brain cholesterol or derivative
level is also inconsistent among studies using AD brains (Sven-
nerholm and Gottfries, 1994; Sparks, 1997; Mulder et al., 1998;
Papassotiropoulos et al., 2002; Schonknecht et al., 2002; Teunis-
sen et al., 2003; Vega et al., 2003; Cutler et al., 2004; Dietschy and
Turley, 2004; Kölsch et al., 2004, 2010; Leoni et al., 2006; Vance
et al., 2006). One of the aims of these observations is the deter-
mination of optimal cholesterol levels for the prevention of AD.
Some studies reported that a high systemic cholesterol level or
high-density lipoprotein (HDL) cholesterol level is associated with
longevity and is also protective against AD development in very
elderly people, suggesting different roles of cholesterol at differ-
ent ages (Weverling-Rijnsburger et al., 1997; Reitz et al., 2010). It is
noteworthy that some statins can increase plasmaHDL level (Jones
et al., 1998). On the other hand, a high midlife serum cholesterol
level has been reported to be a risk factor for the incidence of ADor
AD-related pathological changes (Kivipelto et al., 2002; Pappolla
et al., 2003). This was conﬁrmed by a recent meta-analysis (Anstey
et al., 2008). Therefore, the possible preventive effects of statins
on AD might be related to regulation of cholesterol metabolism in
midlife.
One inevitable point that must be considered is that cholesterol
itself seems to be very important for brain function and main-
tenance (Dietschy and Turley, 2004; Vance et al., 2006). In fact,
a marked reduction of cholesterol levels by high doses of statins
seems to decrease neurotropic support and prove toxic for neurons
(Fan et al., 2001; Suzuki et al., 2004). This might correspond with
some case reports andprospective studies observing adverse effects
of statins, particularly brain-permeable simvastatin and strong
cholesterol-lowering atorvastatin, on cognitive function in espe-
cially elderly patients with dementia (Wagstaff et al., 2003; Evans
and Golomb, 2009; Padala et al., 2012). Following these reports,
the U.S. Food and Drug Administration (FDA) recently added
safety warnings to statins concerning confusion and memory loss.
Such potential adverse effects on cognitive function should be clar-
iﬁed for the appropriate application of statins for AD prevention
or treatment.
ApoE, one of the essential players regulating brain cholesterol
metabolism, is the strongest genetic risk factor for AD (Ashford,
2004). The APOE-ε4 allele increases the accumulation of senile
plaques in AD patients as well as in cognitively normal peo-
ple (Reiman et al., 2009; Morris et al., 2010). In the periphery,
apoE,mainly secreted from the liver, regulates systemic cholesterol
metabolism, and is related to dyslipidemia and arteriosclerosis
(Kolovou and Anagnostopoulou, 2007; Kolovou et al., 2008). In
APOE-ε4 carriers, plasma LDL cholesterol levels are around 10%
higher, due to differences in apoE distribution in cholesterol-lipid
particles and the metabolism of apoE-containing lipid particles
(Cullen et al., 1998; Lucic et al., 2007). Therefore, such increase
of plasma cholesterol level in APOE-ε4 carriers might be a tar-
get for prevention of AD. In the brain, apoE plays important
roles in brain function through lipid transport as HDL-like par-
ticles (Raber et al., 2000; Ji et al., 2003; Bu, 2009; Filippini et al.,
2009;Verghese et al., 2011;Wisdomet al., 2011; Trachtenberg et al.,
2012). We showed that statin treatment increased LDLR-related
protein 1 (LRP1, one of the apoE receptors)-mediated clearance
of Aβ (Shinohara et al., 2010). Interestingly, a prospective study
reported that the risk reduction of AD by statins was observed
only in subjects with the APOE-ε4 allele (Li et al., 2004). On
the other hand, APOE-ε4 carriers seem to be less responsive to
statins in the regulation on lipids (Hubacek and Vrablik, 2011).
Therefore, these studies might suggest a possible action of statins
on amyloid burden through modulation of the apoE-cholesterol
pathway.
PLEIOTROPIC EFFECTS OF STATINS
Oxidative stress, inﬂammatory stress, and statins
Oxidative stress and inﬂammation are thought to be tightly linked
to the pathogenesis and development of AD (Zhu et al., 2007;
Pratico, 2008; Bennett et al., 2009; Heneka et al., 2010; Imbimbo
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et al., 2010). More importantly,many epidemiological studies sug-
gest that anti-oxidative drugs and anti-inﬂammatory drugs may
reduce the risk of AD. One randomized clinical trial suggested
that anti-oxidative drugs (vitamin E and selegiline) might slow
the progression of AD (Sano et al., 1997). However, a recent ran-
domized clinical trial failed to show any beneﬁcial effect of vitamin
E on the conversion of mild cognitive impairment (MCI) to AD
(Petersen et al., 2005). Controversy also exists among the results of
randomized prevention trials of anti-inﬂammatory drugs (Thal
et al., 2005; Lyketsos et al., 2007; Gomez-Isla et al., 2008; Small
et al., 2008). A randomized trial even reported an increased risk
of AD using celecoxib and naproxen, a Cox-2 inhibitor, in people
aged 70 years or older (Lyketsos et al., 2007). This implies that
anti-inﬂammatory drugs may worsen AD by reducing some kind
of beneﬁcial inﬂammation for AD (Akiyama and McGeer, 2004;
Wyss-Coray, 2006), or, as an elderly community-based cohort
study suggested, the increased incidence of AD in later life in anti-
inﬂammatory drug users during midlife may reﬂect delayed effects
of the onset of AD (Breitner et al., 2009). Thus, it remains unde-
termined whether anti-oxidative or anti-inﬂammatory drugs are
beneﬁcial if administered years before the onset of AD, as with
statins.
As noted earlier, several papers showed that an isoprenoid-
dependent mechanism of statins is involved in their anti-oxidative
and anti-inﬂammatory effects. Reactive oxygen species are atten-
uated via the regulation of NADPH by statins (Nakagami et al.,
2003). Statins can also modulate several inﬂammatory responses
via peroxisome proliferator-activated receptor-α and -γ and
nuclear factor-kappa B (Liao and Laufs, 2004; Paumelle and Staels,
2007). In an AD animal study, simvastatin reduced oxidative
stress and inﬂammation in amyloidprecursor protein (APP) trans-
genic mice (Tong et al., 2009). It was also shown that ﬂuvastatin
reduced oxidative damage and ameliorated neuronal degenera-
tion and cognitive dysfunction inAD model mice (Kurinami et al.,
2008). These studies suggest that a possible mechanism of the pre-
ventive action of statins against AD involves anti-oxidative and
anti-inﬂammatory effects via an isoprenoid-dependent pathway.
Effects of statins in vasculature
Vascular impairment is one aspect of AD. Pathologically impaired
vessels have been observed in the brain of AD patients, as repre-
sented by cerebral amyloid angiopathy (CAA). The formation of
CAA might be promoted by impairment of vascular ﬂow (Thal
et al., 2008; Weller et al., 2009). Furthermore, neurovascular cou-
pling, which controls cerebral blood ﬂow in response to neuronal
function, is thought to be involved in the development of AD
(Iadecola, 2004).
Dysfunction of neurovascular coupling can be reversed by anti-
oxidative drugs and anti-inﬂammatory drugs (Iadecola, 2004). In
the Rotterdam study, the HR of AD was reduced by all statins,
regardless of their lipophilicity (Haag et al., 2009). Therefore, the
preventive action of statins on AD could be due to their effects on
brain blood vessels, as hydrophilic statins act more dominantly
on vessels rather than cells inside the brain. Even a lipophilic
statin, simvastatin, improved neurovascular dysfunction in an
AD mouse model, by attenuating oxidative stress and inﬂam-
mation. Importantly, such reversal of neurovascular dysfunction
was associated with improvement of short- and long-term mem-
ory (Tong et al., 2009, 2012). An isoprenoid-dependent effect
is involved in increasing the endothelial nitric oxide synthase
(eNOS) level via the PI3K/Akt pathway, which is important for
vascular function and maintenance (Zhou and Liao, 2010). Li
et al. (2006) showed that simvastatin increased the levels of Akt,
phosphorylated, Akt and eNOS, and reversed learning deﬁcits
in Tg2576 mice, independently of Aβ deposition. Kurata et al.
(2012) also reported that atorvastatin and pitavastatin protected
against degenerations of neurovascular units and reversed learn-
ing deﬁcits in Tg2576 mice. In addition, regulation of systemic
cholesterol by statins might play important roles on preven-
tion of AD by the reduction of cerebrovascular atherosclerosis,
which is reported to correlate with AD pathology, including
senile plaques and CAA (Beach et al., 2007; Yarchoan et al.,
2012). These studies suggest that one of the important actions
of statins with regards to AD could involve blood vessels in the
brain.
Aβ metabolism and statins
The Religious Orders Study, a longitudinal clinical pathologic
study, observed that statin users, especially those using lipophilic
statins, are less likely to have amyloid load in the brain of old
Catholic clergy at autopsy (Arvanitakis et al., 2008). Another study
also showed that cognitively normal people who used statins have
fewer amyloid plaques at autopsy (Li et al., 2007). The mecha-
nism by which statins regulate Aβ metabolism in the brain is
still not fully clariﬁed yet. As with other proteins, the level of
Aβ is determined by the balance of its production and clear-
ance. Blood vessels in the brain play an important role in the
regulation of Aβ clearance (Bell and Zlokovic, 2009; Weller et al.,
2009). Especially, LRP1 could be involved in Aβ clearance by
brain blood vessels (Bell and Zlokovic, 2009). Our recent obser-
vations showed that ﬂuvastatin increased Aβ clearance from the
brain through up-regulating LRP1 level in the brain vessels of
wild-type and APP transgenic mice. The notion that statins
increase LRP1-mediated Aβ clearance was also supported by an
in vitro model of Aβ clearance, using human brain blood ves-
sel cells. In addition, an isoprenoid-dependent pathway mediates
this effect (Shinohara et al., 2010). These results provide evidence
that brain vessels may be directly involved in statins’ action on Aβ
metabolism. Additional studies using conditional LRP1-knockout
mice could clarify the involvement of LRP1 in the enhancement
of Aβ clearance by statins (Kanekiyo et al., 2012). It was also
shown that statins increasedAβ clearance by up-regulating insulin
degrading enzyme, an Aβ-degrading enzyme in vitro (Tamboli
et al., 2010). Taking these ﬁndings together, statins could restore
Aβ clearance, which is reported to be decreased in AD patients
(Mawuenyega et al., 2010).
Many groups also reported that statins regulate Aβ production,
although different mechanisms are proposed. Possible mecha-
nisms include regulation of shedding by α/β/γ-secretase, APP-
trafﬁcking, or degradation of APP-CTFs (C-terminal fragments of
APP) through a cholesterol-dependent or isoprenoid-dependent
mechanism (Kojro et al., 2001; Burns et al., 2006; Parsons et al.,
2006; Ostrowski et al., 2007; Roensch et al., 2007; Won et al., 2008;
Zhou et al., 2008; Guardia-Laguarta et al., 2009). Notably, these
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proposed mechanisms are all based on in vitro culture experi-
ments or animal experiments with high doses of statins. Therefore,
the effect of statins in vivo, at clinically relevant doses, has yet to
be uncovered. Fluvastatin treatment at clinically relevant doses
reduced Aβ production by up-regulating the lysosomal degra-
dation of APP-CTFs in the brain of young C57BL/6 mice. This
effect was mediated by an isoprenoid-dependent pathway, simi-
larly to the up-regulation of LRP1. Changes in the intracellular
distribution of APP-CTFs and small GTPases, Rab5 and Rab7
might be explored to further elucidate the mechanisms of this
effect (Shinohara et al., 2010). This result seems to be impor-
tant, as ﬂuvastatin, one of the brain-impermeable hydrophilic
statins, also can modulate the Aβ production pathway in the
brain at a clinical dosage. This effect might be mediated by the
partial inhibition of small GTPases, as Ostrowski et al. (2007)
indicated.
Tau metabolism and statins
Another key target for AD might be NFTs, where tau is hyper-
phosphorylated and forms a ﬁlamentous structure. The degree
of neuronal loss and the severity of dementia correlate with the
accumulation of NFT rather than senile plaques in AD (Braak
and Braak, 1991; Arriagada et al., 1992). Several types of demen-
tia, known as tauopathies, also manifest NFT and neuronal loss
(Dickson, 2009). Regardless of whether NFT is a subsequent,
parallel or separate event to Aβ accumulation, NFT could be
an important target for prevention and treatment of AD (Small
and Duff, 2008; Jack et al., 2013). Statins were reported to reduce
NFT more signiﬁcantly than senile plaques in cognitively nor-
mal subjects (Li et al., 2007). This observation suggests that
statins could prevent tau accumulation more readily than Aβ
accumulation.
Impaired cholesterol metabolism as well as oxidative and
inﬂammatory stress seems to be involved in tau hyperphospho-
rylation (Schneider et al., 2004; Kitazawa et al., 2005; Michikawa,
2006; Ohm and Meske, 2006; Maccioni et al., 2010). Atorvas-
tatin suppressed tau hyperphosphorylation induced by excess
cholesterol in the rat brain (Lu et al., 2010). On the other
hand, Boimel et al. (2009) found that simvastatin and ator-
vastatin reduced NFT and improved cognitive impairment in
a tauopathy mouse model, associated with reduced inﬂam-
mation. However, of note, cell culture studies showed that
high doses of statins cause tau phosphorylation and cell toxic-
ity (Hoglund et al., 2005b; Anstey et al., 2008). These ﬁndings
suggest that optimal doses of statins may prevent tau hyper-
phosphorylation and NFT accumulation via both cholesterol-
and isoprenoid-dependent effects. Although a study reported
that 40 mg/day simvastatin decreased the phospho-tau level in
patients with dyslipidemia without dementia (Riekse et al., 2006),
other studies reported that statins including 20–80 mg/day sim-
vastatin failed to show a decrease of phospho-tau or total tau
level in the cerebrospinal ﬂuid (CSF) in AD patients (Sjogren
et al., 2003; Hoglund et al., 2005b; Serrano-Pozo et al., 2010)
and middle-aged adults with risk of AD (Carlsson et al., 2008).
Taken together, further clinical studies should determine the
optimal doses of statins, taking individual disease stage into
account.
Other genetic factors and statins
In addition to the APOE gene, recent genome-wide associa-
tion studies (GWAS) identiﬁed novel risk genes for AD (Olgiati
et al., 2011). These genes include box-dependent myc-interacting
protein 1 (BIN1), clusterin (CLU, also called apolipopro-
tein J), ATP-binding cassette transporter A7 (ABCA7), com-
plement component receptor 1 (CR1), phosphatidylinositol-
binding clathrin assembly protein (PICALM), and CD33. As
BIN1 and PICALM are involved in intracellular trafﬁcking
at synapses, these genes might modulate APP trafﬁcking or
tau metabolism (Xiao et al., 2012; Chapuis et al., 2013). CR1
and CD33 are key molecules in inﬂammatory cells, such as
microglia (Crehan et al., 2012; Griciuc et al., 2013). CLU and
ABCA7 are thought to play important roles in lipid home-
ostasis (Tanaka et al., 2011b; Yu and Tan, 2012). Kim et al.
(2013) showed that ABCA7 inactivation in macrophages reduced
phagocytic clearance of Aβ and exaggerated Aβ accumulation
in mice. Interestingly, statins are reported to enhance ABCA7-
dependent phagocytosis through the SREBP pathway (Tanaka
et al., 2011a). These studies suggest crosstalk between statins
and ABCA7 in Aβ metabolism. As these genetic factors are
involved in Aβ metabolism, tau metabolism, inﬂammation, and
lipid metabolism, statins may also have crosstalk with these
molecules.
FURTHER STUDY OF PREVENTIVE EFFECT OF STATINS
FOR AD
Whether or not statins are effective for preventing AD is yet to
be conﬁrmed. Our study showed a modest effect of a statin
on Aβ metabolism in C57BL/6 mice and APP transgenic mice
(around 20% reduction of Aβ level in brain; Shinohara et al.,
2010). We also observed that 3 months’ treatment with ﬂuvastatin
(before abundant Aβ plaque deposition) ameliorated impairment
of spatial learning performance inAPP/PS1 mice (Shinohara et al.,
unpublished results). These effects are most likely mediated by
an isoprenoid-dependent pathway (Li et al., 2006). As cholesterol
level is not readily affected by statins in rodents (Endo, 2008),
larger animal models would also be required to demystify the
cholesterol-dependent effects of statins (Murphy et al., 2010).
A surrogate marker for the regulation of Aβ metabolism as
well as other AD-associated abnormalities would help to success-
fully establish preventive effects on AD. Our preliminary animal
studies failed to show that statin treatment affects Aβ levels in
the blood and CSF (unpublished data), whereas brain Aβ level
was reduced by a statin (Shinohara et al., 2010). These experi-
mental results are consistent with the results of clinical studies,
reporting no change in Aβ levels in CSF and plasma by statin
use in AD patients and cognitively normal adults (Ishii et al.,
2003; Sjogren et al., 2003; Hoglund et al., 2004, 2005a; Riekse
et al., 2006; Carlsson et al., 2008; Serrano-Pozo et al., 2010). These
results suggest that Aβ levels in CSF and plasma would not
reﬂect the “anti-Aβ” effect of statins in the brain. Therefore,
amyloid- and tau-PET (positron emission tomography) imaging
(Maruyama et al., 2013; Weiner et al., 2013), and other poten-
tial CSF surrogate markers like soluble form of LRP1 (Sagare
et al., 2007, 2011) – might be helpful. Several markers of oxida-
tive stress, inﬂammation, or vascular plasticity and integrity could
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Table 1 | Summary of presumable beneficial actions of statin use in midlife on AD epidemiological factors.
Targets of statins
Clinical evidence Cholesterol pathway Isoprenoid pathway
Hyperlipidemia High cholesterol in midlife is a risk for AD
(Kivipelto et al., 2002; Pappolla et al., 2003;
Anstey et al., 2008)
Plasma LDL-cholesterol level and HDL
cholesterol level (Jones et al., 1998; Goldstein
and Brown, 2009)
–
APOE -ε4 Promotion of Aβ accumulation and
down-regulation of brain activity (Raber et al.,
2000; Ji et al., 2003; Bu, 2009; Filippini et al.,
2009; Reiman et al., 2009; Morris et al., 2010;
Verghese et al., 2011;Wisdom et al., 2011;
Trachtenberg et al., 2012)
Plasma LDL-cholesterol (Raber et al., 2000) –
Obesity Obesity is a risk for AD, and midlife obesity
promotes brain aging (Dale et al., 2007;
Beydoun et al., 2008)
Plasma LDL, HDL, and apoB (Watts et al.,
2003; Ooi et al., 2008)
PPAR-α (Roglans et al., 2002;
Landrier et al., 2004)
Hypertension Midlife hypertension is a risk for AD (Skoog
et al., 1996; Launer et al., 2000)
– eNOS, endothelin-1, and ROS
(Strazzullo et al., 2007)
Diabetes Diabetes is a risk for AD, and also midlife
diabetes promotes brain aging (Lu et al., 2009;
Nooyens et al., 2010; Debette et al., 2011)
– RAGE, PPAR-α, -γ, NF-κB, and ROS
(Lanati et al., 2010; Takeda et al.,
2011)
Aβ, β-amyloid peptides; AD, Alzheimer’s disease; apoB, apolipoprotein B-100; apoE, apolipoprotein E; eNOS, endothelial nitric oxide synthase; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; NF-κB, nuclear factor-κB; PPAR, peroxisome proliferator-activated protein; RAGE, receptor for advanced glycation end products;
ROS, reactive oxygen species.
Table 2 | Summary of presumable beneficial actions of statin use in midlife on AD pathogenic stress and molecules.
Clinical evidence Targets of statins
Cholesterol pathway Isoprenoid pathway
Oxidative stress
and inﬂammatory
stress
Oxidative stress and inﬂammatory
stress are involved in AD
– Rac1-NADPH and PPAR-α, -γ and NF-κB
(Nakagami et al., 2003; Liao and Laufs, 2004;
Paumelle and Staels, 2007; Kurinami et al.,
2008; Tong et al., 2009)
Vascular system Midlife vascular risk factors
potentiate development of AD
Cholesterol-induced cerebrovascular
atherosclerosis
PI3K/Akt/eNOS pathway (Li et al., 2006; Zhou
and Liao, 2010; Tong et al., 2012)
Tau accumulation Tau starts to accumulate decades
before the onset of AD (Jack et al.,
2013)
Cholesterol-induced tau hyperphosphorylation
(Lu et al., 2010)
Cholesterol-independent anti-inﬂammatory
effects (Boimel et al., 2009)
Aβ accumulation Aβ starts to accumulate decades
before the onset of AD (Jack et al.,
2010)
Cholesterol-involving Aβ production (Racchi
et al., 1997; Simons et al., 1998; Refolo et al.,
2000; Kojro et al., 2001; Shie et al., 2002;
Wahrle et al., 2002)
APP-CTFs degradation via Rho or Rab family,
and Aβ clearance via LRP1 or IDE (Ostrowski
et al., 2007; Shinohara et al., 2010; Tamboli
et al., 2010)
Aβ, β-amyloid peptides; AD, Alzheimer’s disease; APP-CTFs, C-terminal fragments of amyloid precursor protein; eNOS, endothelial nitric oxide synthase; IDE, insulin
degrading enzyme; LRP1, LDLR-related protein 1; NF-κB, nuclear factor-κB; PPAR, peroxisome proliferator-activated protein; Rac1, Ras-related C3 botulinum toxin
substrate 1; NADPH, nicotinamide adenine dinucleotide phosphate; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; Akt, v-akt murine thymoma viral oncogene
homolog.
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FIGURE 1 | Possible modification genetic and non-genetic risk factors
for AD by statins. Statins might modify genetic and non-genetic risk
factors for Alzheimer’s disease (AD). Genetic risk factors for AD include
apolipoprotein E and genes involved in intracellular trafﬁcking, lipid
metabolism, and inﬂammation. Non-genetic risk factors include aging,
diabetes, dyslipidemia in midlife, hypertension, and inﬂammation.
be assessed to deﬁne the beneﬁcial preventive action of statins
against AD.
As mentioned above, statins might transiently impair cognitive
function (Orsi et al., 2001; King et al., 2003; Wagstaff et al., 2003),
especially where the drug is ﬁrstly administered to treat patients
aged over 75 years. This adverse effect remains a rare occurrence
(Rojas-Fernandez and Cameron, 2012). Considering their bene-
ﬁcial effects, statins should be used with close attention to the
emergence of adverse effects in elderly patients.
CONCLUSION
This review describes the probable preventive actions of statins on
AD. These effects could be achievable if statins were administered
decades before the onset of AD or from midlife. Such effects, if
present at all, could be negligible, with a 10–50% reduction in
risk being expected from the positive results of clinical studies.
The preventive effects of statins on AD include the regulation of
Aβ metabolism, tau metabolism, cholesterol metabolism, oxida-
tive and inﬂammatory stress, and vascular plasticity and integrity,
all of which are independently/interdependently involved in the
pathogenesis of AD (Tables 1 and 2). At least some of these effects
could bemediated by regulation of the isoprenoid pathway. There-
fore, exploring the mechanisms by which isoprenoid metabolism
inﬂuences AD pathogenesis may clarify the isoprenoid-dependent
effects of statins on AD (Eckert et al., 2009). Overall, these ﬁnd-
ings reviewed here suggest that administration of statins in midlife
might preventAD in late life bymodifying genetic andnon-genetic
risk factors for AD (Figure 1). However, it still remains unclear
whether statins really prevent AD in prospective well-controlled
clinical studies. At least, it should be clariﬁed whether statins
inhibit Aβ accumulation, tau pathological features and atrophy in
humans. To answer this question, a randomized controlled study
using amyloid PET, tau-PET, and magnetic resonance imaging
(MRI) would be useful. This clinical evaluation could help us to
overcome this devastating disease.
SEARCH STRATEGY AND SELECTION CRITERIA
References for this Review were identiﬁed through searches of
PubMed up to September 2013, with the search terms “((statins)
OR statin) AND Alzheimer’s disease,” “((statins) OR statin) AND
stroke,” “((statins) OR statin) AND Abeta,” “((statins) OR statin)
AND tau,”“((statins) OR statin) AND cholesterol,”“((statins) OR
statin) AND ((apolipoprotein E) OR apoE),”“((statins) OR statin)
AND aging,” “((statins) OR statin) AND ((gender) OR sex),”
“((statins) OR statin) AND obesity,” “((statins) OR statin) AND
hypertension,” “((statins) OR statin) AND diabetes,” “((statins)
OR statin) AND isoprenoid,”“((statins) OR statin) AND ((oxida-
tive) OR inﬂammatory),”“((statins) OR statin) AND (((cognitive
function) OR brain) OR memory),” “((statins) OR statin) AND
((vasculature) OR vascular),” and “((statins) OR statin) AND
((((((BIN1) OR PICALM) OR CD33) OR CR1) OR CLU) OR
ABCA7).” Only papers published in English were reviewed. Clin-
ical studies as well as animal or cell culture studies were included.
Evidence independently reported by several studies (e.g., meta-
analysis) was more emphasized than evidence reported by a single
study.
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